NO934271L - Anvendelse av rensede overflatemodifiseringsmidler for å hindre partikkelaggregering under sterilisering - Google Patents

Anvendelse av rensede overflatemodifiseringsmidler for å hindre partikkelaggregering under sterilisering

Info

Publication number
NO934271L
NO934271L NO934271A NO934271A NO934271L NO 934271 L NO934271 L NO 934271L NO 934271 A NO934271 A NO 934271A NO 934271 A NO934271 A NO 934271A NO 934271 L NO934271 L NO 934271L
Authority
NO
Norway
Prior art keywords
surface modifiers
particle aggregation
during sterilization
aggregation during
prevent particle
Prior art date
Application number
NO934271A
Other languages
English (en)
Norwegian (no)
Other versions
NO934271D0 (no
Inventor
Kenneth Robert Hollister
David L Ladd
Gregory L Mcintire
George C Na
Natarajan Rajagopalan
Barbara O-Ching Yuan
Original Assignee
Sterling Winthrop Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Winthrop Inc filed Critical Sterling Winthrop Inc
Publication of NO934271D0 publication Critical patent/NO934271D0/no
Publication of NO934271L publication Critical patent/NO934271L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
NO934271A 1992-12-16 1993-11-25 Anvendelse av rensede overflatemodifiseringsmidler for å hindre partikkelaggregering under sterilisering NO934271L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/991,639 US5352459A (en) 1992-12-16 1992-12-16 Use of purified surface modifiers to prevent particle aggregation during sterilization

Publications (2)

Publication Number Publication Date
NO934271D0 NO934271D0 (no) 1993-11-25
NO934271L true NO934271L (no) 1994-06-17

Family

ID=25537416

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934271A NO934271L (no) 1992-12-16 1993-11-25 Anvendelse av rensede overflatemodifiseringsmidler for å hindre partikkelaggregering under sterilisering

Country Status (17)

Country Link
US (1) US5352459A (fr)
EP (1) EP0605024A3 (fr)
JP (1) JPH06211647A (fr)
KR (1) KR940013541A (fr)
AU (1) AU663010B2 (fr)
CA (1) CA2102356A1 (fr)
CZ (1) CZ261693A3 (fr)
FI (1) FI935306A (fr)
HU (1) HUT65783A (fr)
IL (1) IL107518A0 (fr)
MY (1) MY110452A (fr)
NO (1) NO934271L (fr)
NZ (1) NZ250116A (fr)
PH (1) PH30282A (fr)
RU (1) RU2114612C1 (fr)
SK (1) SK141693A3 (fr)
TW (1) TW438606B (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0602700A3 (fr) * 1992-12-17 1994-12-21 Sterling Winthrop Inc Préparation de formulations contrastantes aux rayons-X pour le sang contenant des nanoparticules de tensioactifs à haut poids moleculaire.
EP0600532A3 (fr) * 1992-12-04 1995-02-22 Sterling Winthrop Inc Application d'agents modificateurs du point de trouble ionique pour la prévention d'agrégation des particles pendant la stérilisation.

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5525559A (en) * 1993-02-13 1996-06-11 Tioxide Specialties Limited Preparation of mixed powders
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
JP4484247B2 (ja) * 1995-02-24 2010-06-16 エラン ファーマ インターナショナル，リミティド ナノ粒子分散体を含有するエアロゾル
US5766629A (en) 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
GB9603547D0 (en) * 1996-02-20 1996-04-17 Nycomed Imaging As Contrast media
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
GB9705340D0 (en) * 1997-03-14 1997-04-30 Nycomed Imaging As Compositions
WO1998048847A1 (fr) * 1997-04-25 1998-11-05 Nycomed Imaging As Composition de nanoparticules contenant une substance de contraste de rayons x iodee destinee a une sterilisation thermique
GB9712981D0 (en) * 1997-06-19 1997-08-27 Nycomed Imaging As Compositions
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
ATE259220T1 (de) 1998-05-29 2004-02-15 Skyepharma Canada Inc Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
PL205109B1 (pl) 1998-11-02 2010-03-31 Elan Pharma Int Ltd Wielocząstkowa kompozycja metylofenidatu o modyfikowanym uwalnianiu i jej zastosowanie
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6969529B2 (en) 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
AR035642A1 (es) 2000-05-26 2004-06-23 Pharmacia Corp Uso de una composicion de celecoxib para el alivio rapido del dolor
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
JP2004518642A (ja) * 2000-12-06 2004-06-24 ファルマシア・コーポレーション ラボラトリースケールの微粉砕化プロセス
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
DK1429731T3 (da) * 2001-09-19 2007-05-14 Elan Pharma Int Ltd Nanopartikelformuleringer indeholdende insulin
WO2003026662A1 (fr) * 2001-09-25 2003-04-03 Pharmacia Corporation Formes a l'etat solide du n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
CA2461349C (fr) 2001-09-26 2011-11-29 Baxter International Inc. Preparation de nanoparticules submicroniques par dispersion et elimination d'un solvant ou d'une phase liquide
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
WO2003030872A2 (fr) * 2001-10-12 2003-04-17 Elan Pharma International Ltd. Compositions combinant des caracteristiques de liberation immediate et de liberation prolongee
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
JP2005519657A (ja) * 2001-11-07 2005-07-07 インコール ファーマシューティカル カンパニー ナノ微粒子造影剤を用いた血管撮像の方法
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
ATE464880T1 (de) 2002-02-04 2010-05-15 Elan Pharma Int Ltd Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
AU2003222027A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
AU2003224808A1 (en) * 2002-03-28 2003-10-13 Imcor Pharmaceutical Company Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
AU2003230885A1 (en) 2002-04-12 2003-10-27 Elan Pharma International Ltd. Nanoparticulate megestrol formulations
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
WO2003094894A1 (fr) * 2002-05-06 2003-11-20 Elan Pharma International Ltd. Formulations de nystatine nanoparticulaires
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
CA2488498A1 (fr) * 2002-06-10 2003-12-18 Elan Pharma International Limited Formulation de polycosanol nanoparticulaires et nouvelles combinaisons de polycosanol
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US7713551B2 (en) * 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
WO2004032980A1 (fr) * 2002-10-04 2004-04-22 Elan Pharma International Limited Irradiation gamma d'agents actifs nanoparticulaires solides
ES2365012T3 (es) * 2002-11-12 2011-09-20 Elan Pharma International Limited Formas farmacéuticas sólidas de desintegración rápida que no son friables y que comprenden pululano.
AU2003297151A1 (en) * 2002-12-17 2004-07-22 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
JP4469846B2 (ja) * 2003-01-31 2010-06-02 エラン ファーマ インターナショナル，リミティド ナノ粒子状トピラメート製剤
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US7842232B2 (en) * 2003-05-22 2010-11-30 Elan Pharma International, Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
CA2534924A1 (fr) * 2003-08-08 2005-02-24 Elan Pharma International Ltd. Nouvelles compositions de metaxalone
WO2005044234A2 (fr) * 2003-11-05 2005-05-19 Elan Pharma International Ltd. Compositions nanoparticulaires comprenant un peptide comme stabilisant de surface
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
KR20130030305A (ko) * 2004-11-16 2013-03-26 엘란 파마 인터내셔널 리미티드 주사가능한 나노입자형 올란자핀 제형
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
US20060159766A1 (en) * 2004-12-15 2006-07-20 Elan Pharma International Limited Nanoparticulate tacrolimus formulations
WO2006069098A1 (fr) * 2004-12-22 2006-06-29 Elan Pharma International Ltd. Formulations de la bicalutamide nanoparticulaire
WO2006074218A2 (fr) * 2005-01-06 2006-07-13 Elan Pharma International Ltd. Formulations nanoparticulaires de candesartan
EP1853234A2 (fr) 2005-02-15 2007-11-14 Elan Pharma International Limited Formulations aerosol et injectables de nanoparticules de benzodiazepine
WO2006099121A2 (fr) * 2005-03-10 2006-09-21 Elan Pharma International Limited Preparations de finasteride, de dutasteride et de chlorhydrate de tamsulosine nanoparticulaires et de melanges de ceux-ci
EP1863450A1 (fr) * 2005-03-16 2007-12-12 Elan Pharma International Limited Formulations nanoparticulaires d'un antagoniste du recepteur de leukotriene/d'un corticosteroide
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
KR20070121786A (ko) * 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 코르티코스테로이드 및 항히스타민 제제
MX2007012762A (es) * 2005-04-12 2008-01-14 Elan Pharma Int Ltd Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CA2604735A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Formules de nanoparticules de derives de quinazoline
EP1888037A2 (fr) * 2005-05-10 2008-02-20 Elan Pharma International Limited Formulations de nanoparticules de clopidogrel
US20110064803A1 (en) * 2005-05-10 2011-03-17 Elan Pharma International Limited. Nanoparticulate and controlled release compositions comprising vitamin k2
CA2610480A1 (fr) * 2005-06-03 2007-05-10 Scott Jenkins Preparations nanoparticulaires a base d'acetaminophene
US20070042049A1 (en) * 2005-06-03 2007-02-22 Elan Pharma International, Limited Nanoparticulate benidipine compositions
ATE459341T1 (de) * 2005-06-03 2010-03-15 Elan Pharma Int Ltd Nanoteilchenförmige imatinib-mesylat- formulierungen
WO2008073068A1 (fr) 2005-06-08 2008-06-19 Elan Pharma International Limited Compositions à nanoparticules et à libération contrôlée comprenant du cefditoren
US20070059371A1 (en) * 2005-06-09 2007-03-15 Elan Pharma International, Limited Nanoparticulate ebastine formulations
US20070003615A1 (en) * 2005-06-13 2007-01-04 Elan Pharma International Limited Nanoparticulate clopidogrel and aspirin combination formulations
EP1931340A2 (fr) * 2005-06-15 2008-06-18 Elan Pharma International Limited Formulations d'azelnidipine nanoparticulaire
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
EP1933814A2 (fr) 2005-09-15 2008-06-25 Elan Pharma International Limited Formulations aripiprazoliques nanoparticulaires
EP1959966B1 (fr) * 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Formes galéniques de ganaxolone et procédés de preparation et d'utilisation de celles-ci
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
EP2101735A2 (fr) * 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Formulations de nanoparticules et procédés de préparation et d'utilisation de celles-ci
US8703204B2 (en) 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135828A2 (fr) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticules comprenant un médicament, de l'éthylcellulose et un sel biliaire
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
WO2008149192A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable
WO2008149230A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
WO2009032246A2 (fr) 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Compositions et procédés d'administration de médicaments faiblement solubles
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
WO2009073215A1 (fr) 2007-12-06 2009-06-11 Bend Research, Inc. Compositions pharmaceutiques comprenant des nanoparticules et une matière de remise en suspension
EP2240162A4 (fr) 2007-12-06 2013-10-09 Bend Res Inc Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
MX2010009848A (es) * 2008-03-21 2010-09-30 Elan Pharma Int Ltd Composiciones para el suministro especifico en sitio de imatinib y metodos de uso.
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US20120065221A1 (en) 2009-02-26 2012-03-15 Theraquest Biosciences, Inc. Extended Release Oral Pharmaceutical Compositions of 3-Hydroxy-N-Methylmorphinan and Method of Use
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
HUE032426T2 (en) 2009-05-27 2017-09-28 Alkermes Pharma Ireland Ltd Inhibition of flake aggregation in nanoparticulate meloxicam formulations
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
JP6166721B2 (ja) 2011-07-22 2017-07-19 ケモセントリックス， インコーポレイテッド ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の多形
EP2748146B1 (fr) 2011-07-22 2017-03-08 ChemoCentryx, Inc. Forme cristalline du sel de sodium du 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phényl]-benzènesulfonamide
EP2751094B1 (fr) 2011-09-01 2018-06-20 Glaxo Group Limited Nouvelle forme de cristal
CN103376650B (zh) * 2012-04-25 2016-03-02 东京应化工业株式会社 遮光层形成用感光性基材组合物的制造方法
US9251937B2 (en) * 2012-06-29 2016-02-02 General Electric Company Heat stable nanoparticle preparations and associated methods thereof
EP2919788A4 (fr) 2012-11-14 2016-05-25 Univ Johns Hopkins Méthodes et compositions pour le traitement de la schizophrénie
KR102493854B1 (ko) 2014-06-25 2023-01-30 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 (s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
EP3191480A1 (fr) 2014-09-08 2017-07-19 GlaxoSmithKline Intellectual Property Development Limited Formes cristallines de 2-(4-(4-éthoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophényl)-n-(5-(1,1,1-trifluoro-2-méthylpropan-2-yl)isoxazol-3-yl)acétamide
CN107709344B (zh) 2015-05-01 2022-07-15 共晶制药股份有限公司 用于治疗黄病毒科病毒和癌症的核苷类似物
CA3001722A1 (fr) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Formulations injectables de neurosteroide contenant des nanoparticules
AU2017311412B2 (en) 2016-08-11 2023-05-18 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
JP6784553B2 (ja) * 2016-09-20 2020-11-11 第一工業製薬株式会社 セルロースナノファイバー濃縮物の製造方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
WO2021026124A1 (fr) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone destinée à être utilisée dans le traitement de l'état de mal épileptique
CA3158280A1 (fr) 2019-12-06 2021-06-10 Alex Aimetti Ganaxolone destinee a etre utilisee dans le traitement du complexe de la sclerose tubereuse
EP4178540A1 (fr) * 2020-07-09 2023-05-17 JANSSEN Pharmaceutica NV Formulations à action prolongée

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2966564D1 (en) * 1978-11-20 1984-02-23 American Home Prod Therapeutic compositions with enhanced bioavailability and process for their preparation
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600532A3 (fr) * 1992-12-04 1995-02-22 Sterling Winthrop Inc Application d'agents modificateurs du point de trouble ionique pour la prévention d'agrégation des particles pendant la stérilisation.
EP0602700A3 (fr) * 1992-12-17 1994-12-21 Sterling Winthrop Inc Préparation de formulations contrastantes aux rayons-X pour le sang contenant des nanoparticules de tensioactifs à haut poids moleculaire.

Also Published As

Publication number Publication date
EP0605024A2 (fr) 1994-07-06
IL107518A0 (en) 1994-02-27
SK141693A3 (en) 1994-09-07
RU2114612C1 (ru) 1998-07-10
CZ261693A3 (en) 1994-07-13
NO934271D0 (no) 1993-11-25
FI935306A (fi) 1994-06-17
CA2102356A1 (fr) 1994-06-17
AU663010B2 (en) 1995-09-21
EP0605024A3 (fr) 1995-04-12
TW438606B (en) 2001-06-07
JPH06211647A (ja) 1994-08-02
PH30282A (en) 1997-02-20
NZ250116A (en) 1994-09-27
US5352459A (en) 1994-10-04
KR940013541A (ko) 1994-07-15
HU9303604D0 (en) 1994-04-28
FI935306A0 (fi) 1993-11-29
HUT65783A (en) 1994-07-28
MY110452A (en) 1998-05-30
AU5046693A (en) 1994-06-30

Similar Documents

Publication Publication Date Title
NO934271L (no) Anvendelse av rensede overflatemodifiseringsmidler for å hindre partikkelaggregering under sterilisering
NO934203L (no) Anvendelse av ioniske slöringspunktmodifiserende midler for å hindre partikkelaggregering under sterilisering
NO934144L (no) Anvendelse av ikke-ioniske slöringspunkt-modifiserende midler for minimalisering av nanopartikkelaggregering under sterilisering
FI971880A (fi) Helposti sulavan kantajan sisältävä farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
NO965455L (no) Butylenoksidetylenoksid-blokk-kopolymer overflateaktive midler som stabiliseringsbelegg for nanokrystallformulering
DK0577215T3 (da) Fremgangsmåde til fremstilling af overflademodificerede anticancer-nanopartikler
HK1002898A1 (en) Novel (r)-5-carbamoyl-8-fluoro-3-n,n-disubstituted-amino-3,4-dihydro-2h-1benzopyranes
ES2086377T3 (es) Procedimiento para tratar o revestir un sustrato con una composicion acuosa y uso de dichas composiciones.
DE69928567D1 (de) Biodegradierbare polyphosphoester-zusammensetzungen zur behandlung von ovarialkrebs
AU2670195A (en) Use of gel formulations as dressing compositions
PL316942A1 (en) Novel pharmaceutic compositions based on taxoides
AU667530B2 (en) Removal of antibodies from blood-derived compositions while retaining coagulation factors
ATE342330T1 (de) Behandlung für substrate
AU3902299A (en) Methods of treating microbial infection and therapeutic formulations therefor
CA2120153A1 (fr) Immunotoxines recombinantes
AU7266991A (en) 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions
AU2003283300A1 (en) Coating composition, particularly for glass surfaces, and methods for the production and use thereof
ATE170194T1 (de) Neue inklusionskomplexe von salzen von nimesulide mit cyclodextrinen
HUT65418A (en) Process for producing inclusion compounds of nimesulide with cyclodextrins and pharmaceutical preparatives containing them
AU1118483A (en) Fabric softening composition
AU2003213661A1 (en) Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
AU2566101A (en) Compounds and methods for the treatment of pain
GB9826245D0 (en) Wood preserative formulations
EP1096021A3 (fr) Mélanines à capacité améliorée d'inhibition de la réplication du HIV